Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

July 2024

Risankizumab induction therapy achieves early symptom improvements that are associated with future clinical and endoscopic outcomes in Crohn's disease: Post hoc analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 studies

J Crohns Colitis 2024;18:818–27 doi: 10.1093/ecco-jcc/jjad206

Rizzo J,

Zhou Q,

Zhang Y,

This post hoc analysis provides additional support for the utility of risankizumab therapy in patients with moderately to severely active CD. Investigators examined the efficacy of risankizumab for providing early symptom relief, along with the prognostic value of early symptom relief for achieving future clinical and endoscopic endpoints.

Keywords:

June 2024

Maintenance risankizumab sustains induction response in patients with Crohn’s disease in a randomized Phase 3 trial

J Crohns Colitis 2024;18:416–423 doi: 10.1093/ecco-jcc/jjad168

Ferrante M,

Irving PM,

Abreu MT,

Axler J,

Gao X,

Cao Q,

Fujii T,

Song A,

Berg S,

Liao X,

Zhou Q,

Kalabic J,

Feagan B,

Panaccione R

Subcutaneous risankizumab maintenance therapy results in durable improvement in clinical and endoscopic outcomes over one year in patients with moderately to severely active Crohn’s disease. Endpoint achievement tended to be achieved in a higher proportion of patients treated with 360mg risankizumab than 160mg risankizumab, and both doses were higher when compared to placebo.